Cognition enhancement by the acetylcholine releaser DuP 996
β Scribed by Leonard Cook; Victor J. Nickolson; George F. Steinfels; Kenneth W. Rohrbach; Victor J. Denoble
- Book ID
- 102818684
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 932 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0272-4391
No coin nor oath required. For personal study only.
β¦ Synopsis
DuP 996, 3,3-Bis(4-pyridinylmethyl)-l -phenylindolin-2-one, a potent in vitro and in vivo releaser of acetylcholine (ACh), dopamine (DA), and serotonin (5HT) in rat brain, significantly enhanced the performance of rats and mice in several behavioral test procedures. At doses of 0.01-0.1 mgikg S.C. DuP 996 protected against a hypoxia-induced passive avoidance deficit in rats. In active avoidance procedures, DuP 996 enhanced acquisition of responses: in rats, at doses between 0.085 and 0.85 mgikg S.C. and 0.25 and 0.85 mgikg p.0.; in mice, at doses between 0.85 and 2.5 mgikg S.C. These effects occurred without any alteration of sensitivity to foot-shock. In addition, DuP 996 prevented a C0,-induced retention deficit of a passive avoidance response when administered prior to acquisition testing.
In a test for acquisition of lever pressing for food in the rat, DuP 996 increased the proportion of animals acquiring this response. Thus, DuP 996 was active in both the shock-and appetitive-motivated procedures and was shown to enhance performance levels when administered post-training as well as before training trials. These results suggest that DuP 996 may be useful in the treatment of cognition dysfunction.
π SIMILAR VOLUMES
DuP 996, in micromolar concentrations, enhances the K'-stimulated release of acetylcholine (ACh) in rat cerebral cortex, hippocampus, and caudate nucleus slices in vitro, without effect on basal release. DuP 996 has very weak affinity for rat brain muscarinic or nicotinic receptors and does not inhi
The effect of administration of SM 21 on memory processes was evaluated in the mouse passive avoidance and in the rat social learning tests. SM 21 (10-20 mg kg -1 i.p.) prevented amnesia induced by scopolamine and dicyclomine as tested by the mouse passive avoidance test and prevented memory disrupt
Since physostigmine (Phy) is presently used in the experimental treatment of Alzheimer disease (AD) patients by means of intracerebral ventricular (i.c.v.) administration, we designed a study to determine the effect of the drug administered by the same route on the cholinergic system of the rat brai